{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:08:08Z","timestamp":1793394488922,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:00:00Z","timestamp":1720224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004788","name":"Osaka Medical and Pharmaceutical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004788","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","thrombosisresearch.com","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.thromres.2024.109095","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T12:07:29Z","timestamp":1720267649000},"page":"109095","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Efficacy of unfractionated heparin in patients with moderate sepsis-induced coagulopathy: An observational study"],"prefix":"10.1016","volume":"241","author":[{"given":"Noritaka","family":"Ushio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Yamakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Hisamune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Takasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2024.109095_bb0005","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40560-016-0169-9","article-title":"Characteristics, treatments, and outcomes of severe sepsis of 3195 ICU-treated adult patients throughout Japan during 2011-2013","volume":"4","author":"Hayakawa","year":"2016","journal-title":"J. Intensive Care"},{"key":"10.1016\/j.thromres.2024.109095_bb0010","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.thromres.2019.04.025","article-title":"Japanese Association for Acute Medicine (JAAM) focused outcomes research in emergency Care in Acute Respiratory Distress Syndrome, Sepsis and trauma (FORECAST) study group, role of disseminated intravascular coagulation in severe sepsis","volume":"178","author":"Gando","year":"2019","journal-title":"Thromb. Res."},{"issue":"1","key":"10.1016\/j.thromres.2024.109095_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-016-1415-1","article-title":"Benefit profile of anticoagulant therapy in sepsis: a nationwide multicentre registry in Japan","volume":"20","author":"Yamakawa","year":"2016","journal-title":"Crit. Care"},{"issue":"2","key":"10.1016\/j.thromres.2024.109095_bb0020","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/1076029615591169","article-title":"Design and evaluation of new unified criteria for disseminated intravascular coagulation based on the Japanese Association for Acute Medicine criteria","volume":"22","author":"Umemura","year":"2016","journal-title":"Clin. Appl. Thromb. Hemost."},{"issue":"3","key":"10.1016\/j.thromres.2024.109095_bb0025","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.imbio.2014.10.008","article-title":"Unfractionated heparin attenuates LPS-induced IL-8 secretion via PI3K\/Akt\/NF-kappaB signaling pathway in human endothelial cells","volume":"220","author":"Li","year":"2015","journal-title":"Immunobiology"},{"issue":"2","key":"10.1016\/j.thromres.2024.109095_bb0030","first-page":"913","article-title":"Both UFH and NAH alleviate shedding of endothelial glycocalyx and coagulopathy in LPS-induced sepsis","volume":"19","author":"Huang","year":"2020","journal-title":"Exp. Ther. Med."},{"issue":"1\u20132","key":"10.1016\/j.thromres.2024.109095_bb0035","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11010-011-1024-x","article-title":"Thrombin and vascular inflammation","volume":"359","author":"Popovic","year":"2012","journal-title":"Mol. Cell. Biochem."},{"issue":"4","key":"10.1016\/j.thromres.2024.109095_bb0040","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/CCM.0b013e31819c06bc","article-title":"Unfractioned heparin for treatment of sepsis: a randomized clinical trial (the HETRASE study)","volume":"37","author":"Jaimes","year":"2009","journal-title":"Crit. Care Med."},{"issue":"3","key":"10.1016\/j.thromres.2024.109095_bb0045","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3892\/etm.2013.1466","article-title":"Low-dose heparin as treatment for early disseminated intravascular coagulation during sepsis: a prospective clinical study","volume":"7","author":"Liu","year":"2014","journal-title":"Exp. Ther. Med."},{"issue":"11","key":"10.1016\/j.thromres.2024.109095_bb0050","doi-asserted-by":"crossref","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","article-title":"Surviving Sepsis campaign: international guidelines for Management of Sepsis and Septic Shock 2021","volume":"49","author":"Evans","year":"2021","journal-title":"Crit. Care Med."},{"issue":"3","key":"10.1016\/j.thromres.2024.109095_bb0055","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/jth.13946","article-title":"Optimal patient selection for anticoagulant therapy in sepsis: an evidence-based proposal from Japan","volume":"16","author":"Umemura","year":"2018","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2024.109095_bb0060","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3820\/jjpe.21.23","article-title":"Utilization of MDV data and data quality control","volume":"21","author":"Nakamura","year":"2016","journal-title":"Japanese Journal of Pharmacoepidemiology\/Yakuzai Ekigaku"},{"issue":"5","key":"10.1016\/j.thromres.2024.109095_bb0065","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"issue":"1","key":"10.1016\/j.thromres.2024.109095_bb0070","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1186\/s13054-021-03762-8","article-title":"Trends in the incidence and outcome of sepsis using data from a Japanese nationwide medical claims database-the Japan Sepsis Alliance (JaSA) study group","volume":"25","author":"Imaeda","year":"2021","journal-title":"Crit. Care"},{"issue":"4","key":"10.1016\/j.thromres.2024.109095_bb0075","first-page":"321","article-title":"Underlying disorders, clinical phenotypes, and treatment diversity among patients with disseminated intravascular coagulation","volume":"3","author":"Ohbe","year":"2020","journal-title":"JMA J."},{"issue":"9","key":"10.1016\/j.thromres.2024.109095_bb0080","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017046","article-title":"New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey","volume":"7","author":"Iba","year":"2017","journal-title":"BMJ Open"},{"issue":"7","key":"10.1016\/j.thromres.2024.109095_bb0085","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/00003246-200107000-00002","article-title":"Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care","volume":"29","author":"Angus","year":"2001","journal-title":"Crit. Care Med."},{"issue":"4","key":"10.1016\/j.thromres.2024.109095_bb0090","first-page":"313","article-title":"Time trends of the outcomes and treatment options for disseminated intravascular coagulation: a nationwide observational study in Japan","volume":"3","author":"Yamakawa","year":"2020","journal-title":"JMA J."},{"issue":"8","key":"10.1016\/j.thromres.2024.109095_bb0095","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/jama.2016.0289","article-title":"Sepsis definitions task force, developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for Sepsis and septic shock (Sepsis-3)","volume":"315","author":"Shankar-Hari","year":"2016","journal-title":"JAMA"},{"issue":"10219","key":"10.1016\/j.thromres.2024.109095_bb0100","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","article-title":"Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the global burden of disease study","volume":"395","author":"Rudd","year":"2020","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.thromres.2024.109095_bb0105","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1001\/jama.2017.13836","article-title":"CDC prevention epicenter program, incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014","volume":"318","author":"Rhee","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.thromres.2024.109095_bb0110","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13054-023-04385-x","article-title":"China critical care clinical trials, national incidence and mortality of hospitalized sepsis in China","volume":"27","author":"Weng","year":"2023","journal-title":"Crit. Care"},{"issue":"11","key":"10.1016\/j.thromres.2024.109095_bb0115","doi-asserted-by":"crossref","DOI":"10.1097\/CCE.0000000000000788","article-title":"Accuracy of international classification of diseases, 10th revision codes for identifying Sepsis: a systematic review and meta-analysis","volume":"4","author":"Liu","year":"2022","journal-title":"Crit. Care Explor."},{"issue":"10","key":"10.1016\/j.thromres.2024.109095_bb0120","doi-asserted-by":"crossref","first-page":"690","DOI":"10.7326\/M13-1581","article-title":"Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study","volume":"161","author":"Lamberts","year":"2014","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.thromres.2024.109095_bb0125","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11239-019-01885-y","article-title":"Assessing the accuracy of ICD-10 codes for identifying acute thromboembolic events among patients receiving anticoagulation therapy","volume":"48","author":"Lawrence","year":"2019","journal-title":"J. Thromb. Thrombolysis"},{"issue":"12","key":"10.1016\/j.thromres.2024.109095_bb0130","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/jamainternmed.2021.6203","article-title":"HEP-COVID Investigators, efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial","volume":"181","author":"Spyropoulos","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.thromres.2024.109095_bb0135","doi-asserted-by":"crossref","unstructured":"ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators; P.R. Lawler, E.C. Goligher, J.S. Berger, M.D. Neal, B.J. McVerry, J.C. Nicolau, M.N. Gong, et al., Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19, N. Engl. J. Med. 385 (9) (2021) 790\u2013802. doi:https:\/\/doi.org\/10.1056\/NEJMoa2105911.","DOI":"10.1056\/NEJMoa2105911"},{"key":"10.1016\/j.thromres.2024.109095_bb0140","doi-asserted-by":"crossref","unstructured":"REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators; E.C. Goligher, C.A. Bradbury, B.J. McVerry, P.R. Lawler, J.S. Berger, M.N. Gong, M. Carrier, et al., Therapeutic anticoagulation with heparin in critically ill patients with Covid-19, N. Engl. J. Med. 385 (9) (2021) 777\u2013789. doi:https:\/\/doi.org\/10.1056\/NEJMoa2103417.","DOI":"10.1056\/NEJMoa2103417"},{"key":"10.1016\/j.thromres.2024.109095_bb0145","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.thromres.2016.11.007","article-title":"Coagulation and sepsis","volume":"149","author":"Levi","year":"2017","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2024.109095_bb0150","doi-asserted-by":"crossref","first-page":"16037","DOI":"10.1038\/nrdp.2016.37","article-title":"Disseminated intravascular coagulation","volume":"2","author":"Gando","year":"2016","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"15","key":"10.1016\/j.thromres.2024.109095_bb0155","first-page":"1869","article-title":"KyberSept trial study group, caring for the critically ill patient","volume":"286","author":"Warren","year":"2001","journal-title":"High-dose antithrombin III in severe sepsis: a randomized controlled trial, JAMA."},{"issue":"10","key":"10.1016\/j.thromres.2024.109095_bb0160","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM200103083441001","article-title":"Recombinant human protein C worldwide evaluation in severe Sepsis (PROWESS) study group, recombinant human protein, efficacy and safety of recombinant human activated protein C for severe sepsis","volume":"344","author":"Bernard","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.thromres.2024.109095_bb0165","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.290.2.238","article-title":"OPTIMIST trial study group, efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial","volume":"290","author":"Abraham","year":"2003","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.thromres.2024.109095_bb0170","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2019.5358","article-title":"Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: the SCARLET randomized clinical trial","volume":"321","author":"Vincent","year":"2019","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.thromres.2024.109095_bb0175","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/jth.13230","article-title":"Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials","volume":"14","author":"Umemura","year":"2016","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2024.109095_bb0180","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/jth.13950","article-title":"Antithrombin concentrate use in disseminated intravascular coagulation of sepsis: meta-analyses revisited","volume":"16","author":"Wiedermann","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.109095_bb0185","article-title":"Favorable outcomes of anticoagulation with unfractioned heparin in sepsis-induced coagulopathy: a retrospective analysis of MIMIC-III database","volume":"8","author":"Peng","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.thromres.2024.109095_bb0190","article-title":"Early prophylactic anticoagulation with heparin alleviates mortality in critically ill patients with sepsis: a retrospective analysis from the MIMIC-IV database, burns","volume":"10","author":"Zou","year":"2022","journal-title":"Trauma"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824002275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824002275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T10:30:43Z","timestamp":1732357843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384824002275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":38,"alternative-id":["S0049384824002275"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2024.109095","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of unfractionated heparin in patients with moderate sepsis-induced coagulopathy: An observational study","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2024.109095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109095"}}